Digital Health Technologies for Charcot-Marie-Tooth (CMT) Disease

by | May 15, 2024 | 0 comments

Digital Health Technologies for Charcot-Marie-Tooth (CMT) Disease

Patients attending the Clinical Trial Readiness Summit will be eligible to participate in this two-week study. All participants will join the clinical researchers and HNF staff for a private dinner on Friday night and will receive a $50 Amazon gift card upon completion of the study.

Wearable-based Remote Monitoring Upper and Lower Limb Function in CMT Pilot Study launches at CMT Clinical Trial Readiness Summit, June 7th & 8th.

The Hereditary Neuropathy Foundation, (HNF)  is advancing digital health technologies and biomarkers for Charcot-Marie-Tooth (CMT) disease using FDA-registered wearable devices in a new partnership with BioSensics™.

CMT is a genetically heterogeneous motor and sensory neuropathy characterized by progressive sensory loss and weakness of the legs and arms causing gait difficulties, frequent falls, balance impairment, and hand weakness. Currently, barriers to clinical trial success still exist including travel, cost restrictions, sensitive outcome measures, and retention. HNF aims to close these gaps and derisk upcoming clinical trials for CMT with emerging wearable technologies.

As a starting point, BioSensics and HNF will launch a pilot research digital wearable study to establish the initial clinical validity of BioSensics wearable devices, PAMSys and LEGSys, in CMT. Comparable to the size and weight of a smartwatch, these devices can be easily worn on the wrist, ankles, or as a neck pendant. Participants will receive their devices with on-site training at the first CMT Clinical Trial Readiness Summit on June 7-8 in San Diego, CA.

“HNF has a strong history of being productive and impactful with the CMT stakeholder community utilizing the Global Registry for Inherited Neuropathies (GRIN) patient registry, our training & research in patient engagement, and lessons learned from failed clinical trials for over a decade. This study is an exciting extension of this work,” said Allison Moore, Founder/CEO of HNF.

“We are honored to work with HNF on this exciting project that promises to change the future of clinical trials for CMT and other neuromuscular diseases”, said Ashkan Vaziri, Ph.D., Founder/CEO of BioSensics.

About BioSensics:

BioSensics is the leader in developing wearable sensors and digital health technologies for clinical trials and research, remote patient monitoring, and health assessments. Founded in 2007 by three scientists from Harvard, BioSensics has created new paradigms in using wearable sensors in healthcare and revolutionized the medical alert industry by creating technologies that are now used by thousands of older adults. BioSensics is the only company that offers comprehensive end-to-end solutions and services for the acquisition of digital measures and biomarkers in clinical trials and research. BioSensics designs and validates all elements of their solutions, including wearable sensors, software, and algorithms. Our experienced research team extends complete scientific and technical consultation services, such as study design and protocol development, in addition to statistical analysis. Furthermore, the BioSensics clinical operations team provides comprehensive operational and logistics support for clinical trial projects. BioSensics has received over $50M in research and development program support from the U.S. National Institute of Health (NIH). In 2022, BioSensics was chosen by NIH to create remote measurement technologies for use in clinical trials involving people with rare diseases.

Learn more on this topic

Related Blog Posts

HNF is Reshaping Drug Repurposing for CMT

HNF is Reshaping Drug Repurposing for CMT

HNF has partnered with Rarebase, a public benefit precision medicine company that has screened a large library of FDA approved small molecules to identify candidates for various types of CMT. Their tech-enabled drug discovery platform is called Function™. There are many published discoveries on the genetic cause of many types of CMT, including an understanding of the basic mechanism of disease and potential targets for FDA-approved drug repurposing. It is this understanding that allows HNF and Rarebase to target the genetic root cause of CMT.

Join the conversation

Leave a Comment


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news